CAR T Cell Therapy
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
3100%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Precision BioSciencesDURHAM, NC
1 program1
anti-BCMA/CD70-CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
GS
Gilead SciencesFOSTER CITY, CA
2 programsNeurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and BeyondN/ACell Therapy1 trial
Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and BeyondN/ACell Therapy
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
Precision BioSciencesanti-BCMA/CD70-CAR-T cells
Gilead SciencesNeurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond
Clinical Trials (2)
Total enrollment: 28 patients across 2 trials
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Start: Apr 2025Est. completion: Apr 202818 patients
Phase 1Recruiting
NCT07375628Gilead SciencesNeurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond
Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond
Start: Feb 2026Est. completion: May 202910 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 28 patients
2 companies competing in this space